{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:30Z","timestamp":1782276450146,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["AA028007"],"award-info":[{"award-number":["AA028007"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01AA014106"],"award-info":[{"award-number":["U01AA014106"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AA028007"],"award-info":[{"award-number":["AA028007"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AA014106"],"award-info":[{"award-number":["U01AA014106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007623","name":"School of Medicine, Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA275777"],"award-info":[{"award-number":["T32CA275777"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.apsb.2025.05.020","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T12:10:14Z","timestamp":1748261414000},"page":"5036-5049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligand"],"prefix":"10.1016","volume":"15","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-1712","authenticated-orcid":false,"given":"Yinlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2038-9933","authenticated-orcid":false,"given":"Mostafa M.H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0614-3335","authenticated-orcid":false,"given":"Ahmad F.","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guocong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-0487","authenticated-orcid":false,"given":"April T.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Daunais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-341X","authenticated-orcid":false,"given":"Yihan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongzhao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achi","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3077-742X","authenticated-orcid":false,"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan I.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Corfas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-6315","authenticated-orcid":false,"given":"Steven H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.05.020_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.apsb.2025.05.020_bib2","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1101\/gad.183509.111","article-title":"On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1","volume":"26","author":"Luo","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2025.05.020_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13072-024-00550-w","article-title":"Transcriptional regulation mechanism of PARP1 and its application in disease treatment","volume":"17","author":"Lu","year":"2024","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.apsb.2025.05.020_bib4","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.3390\/biom2040524","article-title":"Functional Aspects of PARP1 in DNA repair and transcription","volume":"2","author":"Ko","year":"2012","journal-title":"Biomolecules"},{"key":"10.1016\/j.apsb.2025.05.020_bib5","doi-asserted-by":"crossref","first-page":"194257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.apsb.2025.05.020_bib6","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","volume":"27","author":"Ledermann","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2025.05.020_bib7","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.ygyno.2020.02.030","article-title":"Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma","volume":"157","author":"Wolford","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.apsb.2025.05.020_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118975","article-title":"Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases","volume":"267","author":"Thapa","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2025.05.020_bib9","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.chembiol.2021.02.004","article-title":"Avoid the trap: targeting PARP1 beyond human malignancy","volume":"28","author":"Kim","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.05.020_bib10","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.05.020_bib11","doi-asserted-by":"crossref","first-page":"82013","DOI":"10.1111\/febs.15716","article-title":"The role of PARP1 in neurodegenerative diseases and aging","volume":"289","author":"Mao","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2025.05.020_bib12","doi-asserted-by":"crossref","first-page":"62453","DOI":"10.1021\/cr5004248","article-title":"New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases","volume":"115","author":"Ryu","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2025.05.020_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36377-4","article-title":"Radiochemistry for positron emission tomography","volume":"14","author":"Rong","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.05.020_bib14","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.1038\/nrd2290","article-title":"Molecular imaging in drug development","volume":"7","author":"Willmann","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.05.020_bib15","first-page":"7","article-title":"Advancements in PARP1 targeted nuclear imaging and theranostic probes","volume":"9","author":"Ambur","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2025.05.020_bib16","doi-asserted-by":"crossref","first-page":"111488","DOI":"10.1016\/j.jfluchem.2006.09.015","article-title":"Fluorine-18 and medical imaging: radiopharmaceuticals for positron emission tomography","volume":"127","author":"Le Bars","year":"2006","journal-title":"J Fluor Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib17","doi-asserted-by":"crossref","first-page":"92580","DOI":"10.1002\/anie.201805501","article-title":"Chemistry for positron emission tomography: recent Advances in 11C-, 18F-, 13N-, and 15O-labeling reactions","volume":"58","author":"Deng","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.05.020_bib18","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1365-2125.2011.04085.x","article-title":"Positron emission tomography molecular imaging for drug development","volume":"73","author":"Matthews","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2025.05.020_bib19","first-page":"6215553","article-title":"(18) F-Labeling of sensitive biomolecules for positron emission tomography","volume":"23","author":"Krishnan","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.apsb.2025.05.020_bib20","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.2967\/jnumed.120.243287","article-title":"Molecular imaging: PARP-1 and beyond","volume":"62","author":"Puentes","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2025.05.020_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114690","article-title":"Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours","volume":"242","author":"Wang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cancers14051129","article-title":"DNA repair enzyme poly(ADP-ribose) polymerase 1\/2 (PARP1\/2)-targeted nuclear imaging and radiotherapy","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2025.05.020_bib23","first-page":"1e210070","article-title":"The development of 18F fluorthanatrace: a PET radiotracer for imaging poly (ADP-ribose) polymerase-1","volume":"4","author":"Lee","year":"2022","journal-title":"Radiol Imag Cancer"},{"key":"10.1016\/j.apsb.2025.05.020_bib24","doi-asserted-by":"crossref","first-page":"133110","DOI":"10.1158\/1078-0432.CCR-19-3484","article-title":"Safety and feasibility of PARP1\/2 imaging with 18F-PARPi in patients with head and neck cancer","volume":"26","author":"Schoder","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.05.020_bib25","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.2967\/jnumed.118.213223","article-title":"PET imaging of PARP expression using 18F-Olaparib","volume":"60","author":"Wilson","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2025.05.020_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1062432","article-title":"Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases","volume":"9","author":"Tong","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2025.05.020_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113898","article-title":"Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2","volume":"227","author":"Yu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib28","first-page":"3328","article-title":"PARP-1 and PARP-2: new players in tumour development","volume":"1","author":"Yelamos","year":"2011","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.apsb.2025.05.020_bib29","doi-asserted-by":"crossref","first-page":"101061949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.05.020_bib30","doi-asserted-by":"crossref","first-page":"222154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.05.020_bib31","doi-asserted-by":"crossref","first-page":"91274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.05.020_bib32","doi-asserted-by":"crossref","first-page":"71144","DOI":"10.1038\/cdd.2014.202","article-title":"PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors","volume":"22","author":"Farres","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2025.05.020_bib33","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.05.020_bib34","doi-asserted-by":"crossref","first-page":"2846348","DOI":"10.18632\/oncotarget.18013","article-title":"PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma","volume":"8","author":"Murnyak","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2025.05.020_bib35","doi-asserted-by":"crossref","first-page":"72081","DOI":"10.1007\/s00259-023-06162-y","article-title":"Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates","volume":"50","author":"Chen","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.apsb.2025.05.020_bib36","article-title":"Discovery, preclinical validation and early human imaging with [11C]AZ14193391 \u2013 the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand","volume":"126\u2013127","author":"Cortes Gonzalez","year":"2023","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.apsb.2025.05.020_bib37","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-5977","article-title":"Abstract 5977: Discovery and preclinical validation of [11C]AZ3391: a first in class blood-brain barrier permeable, subtype selective PARP-1 PET radioligand","volume":"82","author":"Johnstr\u00f6m","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.05.020_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-5076","article-title":"Abstract 5076: evaluation of the CNS penetration of a next generation PARP inhibitor, AZD9574, in cynomolgus monkey using positron emission tomography","volume":"82","author":"Pike","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.05.020_bib39","doi-asserted-by":"crossref","first-page":"71338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood-brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.05.020_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.mibio.2003.09.014","article-title":"Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents","volume":"5","author":"Waterhouse","year":"2003","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.apsb.2025.05.020_bib41","doi-asserted-by":"crossref","first-page":"181818","DOI":"10.2174\/0929867323666160418114826","article-title":"Considerations in the development of reversibly binding PET radioligands for brain imaging","volume":"23","author":"Pike","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib42","first-page":"31712","article-title":"Imaging leucine-rich repeat kinase 2 in vivo with 18F-labeled positron emission tomography ligand","volume":"66","author":"Chen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib43","doi-asserted-by":"crossref","first-page":"1914498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib44","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1101\/gad.9.5.509","article-title":"Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease","volume":"9","author":"Wang","year":"1995","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2025.05.020_bib45","doi-asserted-by":"crossref","first-page":"2411178","DOI":"10.7150\/thno.42587","article-title":"Synthesis and preliminary studies of 11C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.05.020_bib46","doi-asserted-by":"crossref","first-page":"139144","DOI":"10.1021\/acs.jmedchem.2c00377","article-title":"Imaging of transmembrane AMPA receptor regulatory proteins by positron emission tomography","volume":"65","author":"Yu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib48","doi-asserted-by":"crossref","first-page":"62278","DOI":"10.1021\/acs.jmedchem.7b01400","article-title":"In vitro and in vivo evaluation of 11C-labeled azetidinecarboxylates for imaging monoacylglycerol lipase by PET imaging studies","volume":"61","author":"Cheng","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib49","doi-asserted-by":"crossref","first-page":"73336","DOI":"10.1021\/acs.jmedchem.8b01778","article-title":"Design, synthesis, and evaluation of reversible and irreversible monoacylglycerol lipase positron emission tomography (PET) tracers using a \u201ctail switching\u201d strategy on a piperazinyl azetidine skeleton","volume":"62","author":"Chen","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.05.020_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127326","article-title":"Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[11C]methoxyphenethyl)pyridazin-3(2H)-one, a 11C-labeled D-amino acid oxidase (DAAO) inhibitor for PET imaging","volume":"30","author":"Deng","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.05.020_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2021.153007","article-title":"Imaging the trace amine-associated receptor 1 by positron emission tomography","volume":"70","author":"Sun","year":"2021","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.apsb.2025.05.020_bib52","doi-asserted-by":"crossref","first-page":"1914283","DOI":"10.1021\/acs.jmedchem.1c00747","article-title":"Novel reversible-binding PET ligands for imaging monoacylglycerol lipase based on the piperazinyl azetidine scaffold","volume":"64","author":"Rong","year":"2021","journal-title":"J Med Chem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525003260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525003260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:21:09Z","timestamp":1762604469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525003260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2211383525003260"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.05.020","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2024-8pqmg-v2","asserted-by":"object"},{"id-type":"doi","id":"10.26434\/chemrxiv-2024-8pqmg","asserted-by":"object"}]},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligand","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}